title: ATX-101 (deoxycholic acid injection) for reduction of submental fat.
abstract: BACKGROUND
  The shape and contour of the chin and neck play an important role in facial esthetics. As such, excess fat within the submental area (double chin) can negatively affect facial esthetics and body image. Common treatments for submental contouring include invasive procedures such as surgical rejuvenation and targeted liposuction. Energy devices (lasers, radiofrequency, and ultrasound) may be used to improve submental skin laxity while cryolipolysis was recently cleared in the United States for use in the submental area. However, ATX-101 (deoxycholic acid injection) is the only injectable drug approved in the United States and Canada for reduction of submental fat.
  
  
  METHODS
  The efficacy and safety of ATX-101 have been extensively evaluated in a global clinical development program including multiple Phase I/II studies and four large Phase III trials. Available data from ATX-101 trials are reviewed. Expert commentary: Injectables have been well established for facial rejuvenation. Extending injectable treatment into the chin and neck is a major advance for nonsurgical cosmetic correction. Overall, the evidence supports ATX-101 as a safe and effective, minimally invasive treatment alternative for reduction of submental fat that will provide a major tool for the esthetic physician.
authors.affiliation: a Clinic of Aesthetic Surgery IENA , Paris , France.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Ascher
authors.affiliation: b Kythera Biopharmaceuticals, Inc ., Westlake Village , CA , USA (an affiliate of Allergan plc, Dublin, Ireland).
authors.forename: Jere
authors.initials: J
authors.lastname: Fellmann
authors.affiliation: c Private Practice (Total Skin & Beauty Dermatology Center, P.C.) and Department of Dermatology, Department of Ophthalmology , University of Alabama at Birmingham , Birmingham , AL , USA.
authors.forename: Gary
authors.initials: G
authors.lastname: Monheit
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects*; D000818:Animals; D002680:Chin; D003357:Cosmetic Techniques / Q000009:adverse effects; D003840:Deoxycholic Acid / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007267:Injections; D009333:Neck; D016896:Treatment Outcome
chemical_list: C000599116:ATX-101 compound; D003840:Deoxycholic Acid
keywords: ATX-101; Adipocyte lysis; deoxycholic acid; efficacy; facial esthetics; injectable; nonsurgical; safety; submental fat